

IN THE CLAIMS:

a1 a2 --1. (Amended) A composition comprising human monoclonal antibodies that bind ^{specifically} to human tumor necrosis factor alpha.--

a2 --12. (Amended) [An] A human monoclonal antibody preparation characterized by binding specifically to human TNF alpha, and having a titer comparable to three high affinity neutralizing mouse monoclonal antibodies when tested by ELISA.--

Amend claim 11, line 3, by inserting --CRL 11306-- after "ATCC Deposit".

In claim 13, line 4, replace "on" with "or".

IN THE FIGURES:

(NE)
Enter the enclosed formal Figures 12A - 12D on A-4 paper.

IN THE SPECIFICATION:

At page 11, lines 11 and 12, please insert --March 24, 1993-- after the word "on" and insert --CRL 11306-- after the word "deposit".

a2 At page 11, line 15, insert the following sentence: --Hybridoma cell lines F448-1D1-A8 and F80-1B9-F12 were deposited with ATCC on May 11, 1993 and given ATCC Designation HB 11343 and HB 11344, respectively.--